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cules. As a result, free radicals are potentially danger-
ous to living tissue. They are formed during normal
cerebral metabolism but cause injury only when they
F ree radicals are chemical species with one or moreunpaired electrons in their outer orbital. This makes
them unstable and highly reactive with nearby mole-
Objective: The aim of this study was to assess the role of reactive oxygen
species in the impairment of cerebral recovery that follows deep
hypothermic circulatory arrest. Methods: Twelve 1-week-old piglets were
randomized to placebo (control group; n = 6) or 100 mg · kg–1 intra-
venous α-phenyl-tert-butyl nitrone, a free radical spin trap (PBN group;
n = 6). All piglets underwent cardiopulmonary bypass, cooling to 18˚C,
60 minutes of circulatory arrest followed by 60 minutes of reperfusion,
and rewarming. Cerebral blood flow and metabolism were determined
at baseline before deep hypothermic circulatory arrest and after 60 min-
utes of reperfusion. Results: In control animals, mean global cerebral
blood flow (± 1 standard error) before circulatory arrest was 48.4 ± 3.6
mL · 100 g–1 · min–1 and fell to 25.1 ± 3.6 mL · 100 g–1 · min–1 after cir-
culatory arrest (P = .001). Global cerebral metabolism fell from 3.5 ± 0.2
mL · 100 g–1 · min–1 before arrest to 2.2 ± 0.2 mL · 100 g–1 · min–1 after
circulatory arrest (P = .0002). In the PBN group after circulatory arrest,
the mean global cerebral blood flow and metabolism of 37.2 ± 4.9 and
3.6 ± 0.5 mL · 100 g–1 · min–1, respectively, were significantly higher than
in the control group (P < .05). Recovery of cerebral blood flow in the
PBN group was 78% of pre-arrest level compared with 52% in the con-
trol group (P = .002). Global cerebral metabolism after circulatory
arrest was 100% of the pre-arrest value compared with 61% in the con-
trol group (P = .01). Regional recovery of cerebral metabolism in the
cerebellum, brain stem, and basal ganglia was 131%, 130%, and 115%,
respectively, of pre-arrest values in the PBN group compared with 85%,
78%, and 70% in the control group (P < .04). Conclusions: Reactive oxy-
gen species contribute to the impairment of cerebral recovery that fol-
lows deep hypothermic circulatory arrest. The use of α-phenyl-tert-butyl
nitrone before the arrest period attenuates the normal response to
ischemia and improves recovery by affording protection from free rad-
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exceed the antioxidant defenses of the tissue. The
extreme reactivity of free radicals means that they
never accumulate to concentrations sufficient to allow
direct observation. Addition of a free radical to a
nitrone, however, yields a nitroxide species, which can
be detected by electron spin resonance spectroscopy. 
The nitrones were developed in the 1960s specifical-
ly for the indirect detection of short-lived free radical
species. One such nitrone is α-phenyl-tert-butyl
nitrone, or PBN. Chemicals that can combine with free
radicals to allow detection by electron spin resonance
are known as “spin traps,” and the combination of the
free radical with the nitrone is termed a “spin adduct.”
PBN was first described in the context of free radical
spin trapping in 1968.1 Although nitrone spin traps
have been used to detect free radicals since the 1960s,
it was not until 20 years after this that consideration
was given to their therapeutic potential. Neuropro-
tective properties of the nitrones were not described
until the early 1990s.2,3
At least three chemical species, superoxide (O2–),
hydrogen peroxide (H2O2), and hydroxyl (OH) free
radicals, are involved in oxygen-derived free radical
damage in biologic systems. Oxygen-derived free radi-
cals play a key role in the pathologic processes induced
by cerebral ischemia, and the OH radical is the most
important of the oxygen-derived free radicals in this
context. Ischemia-reperfusion injury induces OH radi-
cal formation in brain microvessels.4 Subsequent free
radical damage to the cerebral vasculature causes an
increase in permeability of the blood-brain barrier,5,6
altered membrane ion transport activity,7 and enhanced
neutrophil adhesion to the vascular endothelium.8
In addition to cerebral vascular injury, oxygen-
derived free radicals induce membrane lipid peroxida-
tion.9 Neuronal membranes are particularly susceptible
to free radical attack because they are rich in polyun-
saturated fatty acids. Potential consequences of damage
to membrane lipid include changes in fluidity and per-
meability and in the orientation of proteins embedded
in the bilayer of the plasma membrane and in other cel-
lular endomembranes.10 Other important targets for
free radical attack are proteins, amino acids, nucleic
acid bases, carbohydrates, neurotransmitters, and
DNA.11 The resulting alterations in morphology and
function are potentially lethal, causing neuronal death.
The enhanced propensity of cerebral tissue to peroxi-
dize, the fact that it is intricately and highly organized
and carries out central information processing, plus the
fact that neurons are postmitotic cells combine to make
free radical damage a particularly serious problem in
the brain. 
The generation of free radicals after cerebral
ischemia would appear to be central to the subsequent
vascular and neuronal damage. Scavenging of these
free radicals could offer enormous therapeutic benefit.
The aim of this study was to use PBN to indirectly
assess the role of free radicals in the impairment of
cerebral recovery that is known to follow a period of
deep hypothermic circulatory arrest (DHCA) in chil-
dren.12 The null hypothesis is that free radicals are not
involved in the post-DHCA impairment in cerebral
blood flow (CBF) and cerebral metabolism (CMRO2)
and that PBN given before cardiopulmonary bypass
(CPB) will have no effect on cerebral recovery after 60
minutes of DHCA in the neonatal piglet.
Material and methods
Animal preparation. All animal experiments were con-
ducted with the approval of the Animal Care and Use
Committee of Duke University. The animals received
humane care in compliance with the “Guide for the Care and
Use of Laboratory Animals” published by the National
Institutes of Health (NIH publication 85-23, revised 1995)
and were housed in the institution’s NIH-approved animal
facility before the experiments. 
Twelve neonatal piglets (1-2 weeks old) were anesthetized
with an intramuscular injection of ketamine (50 mg · kg–1)
and acepromazine (15 µg · kg–1). Intravenous methylpred-
nisolone (30 mg · kg–1) was administered via a 24-gauge can-
nula in the marginal vein of the pinna. Orotracheal intubation
was performed and mechanical ventilation (Infant Ventilator,
Sechrist Industries, Anaheim, Calif) was commenced to
achieve arterial oxygen tensions of 150 to 250 mm Hg and
carbon dioxide tensions of 35 to 45 mm Hg. The animals
were paralyzed with intravenous pancuronium (300 µg · kg–1)
and anesthetized with fentanyl (100 µg · kg–1). Thereafter,
anesthesia was maintained with a continuous infusion of fen-
tanyl (25 µg · kg–1 · h–1). An 18-gauge cannula was placed in
the descending aorta via the femoral artery for blood pressure
monitoring and arterial blood sampling. The animal’s tem-
perature was monitored throughout the study by an
indwelling nasopharyngeal temperature probe (Yellow
Springs Instrument Co Inc, Yellow Springs, Ohio).
Temperature was maintained at 36˚C except for the period of
induced hypothermia.
The heart was exposed through a median sternotomy.
Cardiac instrumentation consisted of a 3F micromanometer
(Millar Instruments, Inc, Houston, Tex) inserted into the
superior vena cava for central venous pressure monitoring
and placement of an 8-mm flow probe (Transonic Systems,
Inc, Ithaca, NY) around the proximal pulmonary artery for
cardiac output monitoring.
Sagittal sinus access. The animals were anticoagulated
with intravenous heparin (500 IU/kg) before access of the
sagittal sinus. A 1-cm strip of scalp was raised in the midline
over the vertex of the skull. Two separate 2-mm burr holes
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were made over the superior sagittal sinus for repeated sam-
pling of sagittal sinus venous blood and continuous monitor-
ing of sagittal sinus venous pressure with a 3F micro-
manometer (Millar Instruments).
CPB and circulatory arrest. An 8F arterial cannula and a
20F venous cannula (DLP Inc, Grand Rapids, Mich) were
inserted through purse-string sutures into the ascending aorta
and the right atrium, respectively. CPB was commenced at a
flow rate of 120 mL · kg–1 · min–1. The pump-oxygenator sys-
tem consisted of a Sarns nonpulsatile roller pump (Sarns
Inc/3M Health Care, Ann Arbor, Mich) and a Medtronic
Minimax PLUS hollow-fiber membrane oxygenator
(Medtronic Inc, Anaheim, Calif). No arterial filter was used.
The circuit was primed with heparinized fresh blood from a
donor pig. Ringer’s lactate and sodium bicarbonate solutions
were added to the prime to achieve a hematocrit value of 0.25
and a pH of 7.4 at 37˚C. The total prime volume was approx-
imately 450 mL. The temperature of the perfusate was con-
trolled with the integral heat exchanger in the venous reser-
voir of the oxygenator and a BIO-CAL 370 water bath system
(Medtronic Bio-Medicus, Eden Prairie, Minn). Animals were
cooled to a temperature of 18˚C over a standard duration of
20 minutes by the circulation of ice water through the heat
exchanger. At the end of the cooling period, the circulation
was arrested and blood was drained from the animal. DHCA
was therefore established and the aortic and right atrial can-
nulas were clamped. After 60 minutes of DHCA, the aortic
and venous cannulas were unclamped. Perfusion was re-
established at 120 mL · kg–1 · min–1 with the perfusate ini-
tially at room temperature (20˚C-22˚C). Rewarming was
accomplished by circulating warm water through the heat
exchanger in the venous reservoir. A nasopharyngeal temper-
ature of 36˚C was generally reached by 45 minutes of reper-
fusion. During cooling and rewarming, blood gases were
managed according to the alpha-stat strategy. The arterial pH
was maintained at 7.35 to 7.45 and carbon dioxide tension at
35 to 45 mm Hg, measured at 37˚C and uncorrected for the
temperature of the animal. Arterial oxygen tension was kept
between 150 and 250 mm Hg and hematocrit between 0.23
and 0.28. Sodium bicarbonate (8.4%) was given when neces-
sary but not immediately before CBF measurements. At the
end of the study, the animals were killed by a bolus injection
of fentanyl and cessation of CPB.
Measurement of CBF. CBF measurements were deter-
mined by the reference-sample, radiolabeled microsphere
technique13 during CPB at 36˚C. The technique described in
the current study is the same as that used in previous reports
from our laboratory.14 Suspensions of microspheres with a
diameter of 15.5 ± 0.1 µm (E.I. DuPont de Nemours &
Company, Wilmington, Del) were made up in 10% dextran
and 0.01% TWEEN 80 with 106 microspheres per milliliter.
Two different isotopes were used in each piglet and these
were chosen at random from the three different isotopes
available (46Sc, 103Ru, and 95Nb). For each flow measure-
ment, 106 microspheres were injected into a side port of the
arterial tubing 30 cm proximal to the aortic cannula over 30
seconds and washed through with 5 mL of warm saline solu-
tion. A reference blood sample was withdrawn from the dis-
tal aorta at a constant rate of 3 mL · min–1 with a Harvard
syringe pump (Harvard Apparatus, South Natick, Mass) com-
mencing 10 seconds before the microsphere injection and
continuing for 2 minutes. At the end of the experiment, the
brain was removed and divided into left and right cerebral
hemispheres, basal ganglia, cerebellum, and brain stem (mid-
brain, pons, and medulla oblongata). In addition, the kidneys
were also removed for determination of renal blood flow.
After measurement of fresh weights, the brain parts and kid-
neys were dissolved in 2 mol/L potassium hydroxide solution
and analyzed, together with the reference blood sample, in a
gamma counter (Auto-Gamma 5530; Packard Instrument Co,
Meriden, Conn) to estimate the quantity of each type of radio-
labeled microsphere present in the specimen. The withdrawal
rate of the reference blood sample and the ratio of counts
from a brain part to the reference blood sample allowed cal-
culation of regional CBF. CBF measurements are expressed
in milliliters per 100 g of brain per minute by normalizing for
fresh tissue weight. The weighted sum of regional CBF
allowed calculation of global CBF.
Cerebral perfusion pressure (CPP) was taken as the differ-
ence between the mean arterial pressure and the sagittal sinus
venous pressure. Cerebral vascular resistance (CVR) was the
ratio of CPP to global CBF (in milligrams of mercury per 100
g per minute per milliliter). Systemic vascular resistance was
taken as the ratio between the systemic perfusion pressure
and the total bypass pump flow rate (systemic vascular resis-
tance = [mean arterial pressure – right atrial pressure]/ [pump
flow rate] in millimeters of mercury per 100 g per minute per
milliliter). 
Measurement of cerebral oxygen handling. Arterial and
sagittal sinus blood samples were taken just before each
microsphere injection for estimation of oxygen tension, car-
bon dioxide tension, oxygen saturation, pH, and base excess
by means of a GEM-Stat blood gas/electrolyte monitor
(Mallinckrodt Sensor Systems, Inc, Ann Arbor, Mich).
Hemoglobin levels (in grams per deciliter) were measured
from arterial blood samples (482 Co-Oximeter; Instrumenta-
tion Laboratory Corp, Lexington, Mass). Cerebral delivery of
oxygen (CDO2 in milliliters per 100 g brain per minute), cere-
bral metabolic rate of oxygen (CMRO2 in milliliters per 100
g brain per minute) and cerebral oxygen extraction (CEO2 as
a percent) were calculated as follows:
CDO2 = CBF × arterial oxygen content
CMRO2 = CBF × (arterial oxygen content – 
sagittal sinus venous oxygen content)
CEO2 = (CMRO2/CDO2) × 100%
The oxygen content (in milliliters of oxygen per milliliter
of blood) was calculated by the following formula:
Oxygen content = 0.01 × [(1.36) (hemoglobin) 
(oxygen saturation) + (0.003) (oxygen tension)]
Experimental protocol and data collection. The animals
were randomized into 2 groups with 6 animals in each group.
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The study group received a PBN concentration of 100 mg ·
kg–1 (Sigma Chemical Company, St Louis, Mo) in 5 mL of
normal saline solution intravenously at induction plus an
additional 200 mg · kg–1 in 10 mL of normal saline solution
in the pump. Control animals received 5 mL of normal saline
solution intravenously at induction plus 10 mL in the pump.
All animals were cannulated for CPB, and normothermic per-
fusion was commenced at 120 mL · kg–1 · min–1. The animals
were stabilized on normothermic CPB for a minimum of 20
minutes before the pre-DHCA measurement was taken.
During this time the pump flow was adjusted to provide a
constant CPP of 50 mm Hg. After the pre-DHCA measure-
ment, pump flow was returned to 120 mL · kg–1 · min–1 and
the animals were cooled for DHCA. At the end of 60 minutes
of DHCA, circulation was recommenced and the animals
were rewarmed. At 45 minutes of reperfusion, pump flow rate
was again adjusted to provide a CPP of 50 mm Hg for 15
minutes before the post-DHCA CBF measurement was made
at 60 minutes of reperfusion. Data collected at the two time
points included nasopharyngeal temperature, mean arterial
blood pressure, right atrial pressure, sagittal sinus venous
pressure, arterial and sagittal sinus blood gases, CPB flow
rate, electrolytes, hematocrit, hemoglobin, CBF, and renal
blood flow. 
Statistical analysis. All the results were entered into an
Excel 97 spreadsheet (Microsoft Corporation, Redmond,
Wash) for further analysis. Repeating formulas were set up to
calculate the mean and standard error of the mean for all the
data collected in each animal. Further repeating formulas
were programmed for calculation of the CBF, CDO2, CEO2,
CMRO2, and the percentage change between these, before
and after DHCA, for all animals. A 2-tailed paired samples t
test was used to compare means at different time points with-
in a group. An unpaired (independent samples) t test was used
to compare means between the groups. Statistical signifi-
cance was tested at the 95% confidence limit.
Results
Before the commencement of cooling and DHCA,
there was no significant difference in global CBF,
CVR, cerebral oxygen handling, and renal blood flow
between the 2 groups (P > .21). The nasopharyngeal
temperature, arterial blood gases, pH, hematocrit,
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Table I. Global and regional CBF in control and PBN groups before and after DHCA
Group Pre-DHCA Post-DHCA P value
Global CBF Control 48.4 ± 3.6 25.1 ± 2.4 .0001
PBN 46.9 ± 3.0 37.2 ± 4.9 .01
Hemispheres Control 50.1 ± 2.7 22.6 ± 1.2 .0003
PBN 46.9 ± 2.5 31.0 ± 3.3 .003
Cerebellum Control 55.2 ± 2.5 39.9 ± 3.0 .009
PBN 50.4 ± 2.8 50.9 ± 2.8 .87
Basal ganglia Control 47.1 ± 1.1 27.3 ± 1.3 .0001
PBN 40.2 ± 3.5 34.7 ± 3.0 .19
Brain stem Control 40.6 ± 2.3 26.1 ± 1.3 .001
PBN 36.5 ± 2.1 36.1 ± 2.3 .89
The study group (PBN) received 100 mg · kg–1 α-phenyl-tert-butyl nitrone in 5 mL of normal saline solution intravenously at induction plus an additional 200 mg ·
kg–1 in 10 mL of normal saline solution in the pump. Control animals received 5 mL of normal saline solution intravenously at induction plus 10 mL in the pump.
All animals underwent 60 minutes of DHCA at 18˚C and were rewarmed and reperfused for 1 hour. CBF measurements were all determined at a CPP of 50 mm Hg.
All values are given in units of mL · 100 g–1 · min–1.
Table II. Global cerebral oxygen handling and CVR in control and PBN groups before and after DHCA
Group Pre-DHCA Post-DHCA P value
CDO2 (mL · 100 g–1 · min–1) Control 6.15 ± 0.55 3.19 ± 0.30 .0003
PBN 5.79 ± 0.43 4.97 ± 0.72 .11
CMRO2 (mL · 100 g–1 · min–1) Control 3.53 ± 0.22 2.17 ± 0.20 .0002
PBN 3.61 ± 0.29 3.60 ± 0.50 .98
CEO2 (%) Control 58.3 ± 3.4 68.9 ± 4.3 .03
PBN 62.9 ± 4.1 72.8 ± 3.0 .05
CVR (mm Hg · 100 g · min · mL–1) Control 1.06 ± 0.08 2.03 ± 0.20 .001
PBN 1.08 ± 0.07 1.48 ± 0.22 .05
The study group (PBN) received 100 mg · kg–1 α-phenyl-tert-butyl nitrone in 5 mL of normal saline solution intravenously at induction plus an additional 200 mg ·
kg–1 in 10 mL of normal saline solution in the pump. Control animals received 5 mL of normal saline solution intravenously at induction plus 10 mL in the pump.
All animals underwent 60 minutes of DHCA at 18˚C and were rewarmed and reperfused for 1 hour. CDO2, Cerebral oxygen delivery; CEO2, cerebral oxygen extrac-
tion; CMRO2, cerebral metabolic rate of oxygen; CVR, cerebral vascular resistance. 
hemoglobin, and CPP were also similar in both
groups (P > .29, data not shown). Within each group,
no significant differences (paired samples t test P >
.1) in these variables were detected before and after
DHCA.
Effects of DHCA in the control group. In the con-
trol group, after 1 hour of DHCA the systemic vascular
resistance fell from 0.43 ± 0.03 mm Hg · 100 g · min ·
mL–1 before DHCA to 0.35 ± 0.02 mm Hg · 100 g · min
· mL–1 after DHCA (P = .06). This fall necessitated a
rise in mean pump flow from 137 ± 8 mL · kg–1 · min–1
before DHCA to 170 ± 10 mL · kg–1 · min–1 after
DHCA (P = .04) to maintain the preset CPP of 50 mm
Hg at the time of CBF measurement. CBF was signifi-
cantly reduced to all regions of the brain after DHCA
(P < .009) (Table I). Different brain regions were
affected to varying degrees, with recovery of blood
flow lowest in the cerebral hemispheres and greatest in
the cerebellum (Fig 1). 
Changes in global CDO2, CMRO2, CEO2, and CVR
after DHCA are shown in Table II. Global CDO2 was
significantly lower after 60 minutes of DHCA.
Analysis of the regional CDO2 demonstrated that, in
accordance with CBF, there was regional variation with
a significant difference in CDO2 before and after
DHCA in all regions (P < .02). Recovery in CDO2 var-
ied from only 45.9% ± 3.2% of baseline in the cerebral
hemispheres and 73.2% ± 5.6% of the baseline in the
cerebellum. The mean global CMRO2 also dropped sig-
nificantly after DHCA. The recovery in CMRO2 after
DHCA varied between the brain regions. The percent-
age recovery was highest in the cerebellum and lowest
in the cerebral hemispheres (Fig 2). Both the CEO2 and
the CVR were significantly higher after DHCA.
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Fig 1. Global and regional CBF at 1 hour of reperfusion after 60 minutes of DHCA at 18˚C in control and PBN
groups. Data are expressed as percentage of baseline CBF before DHCA (mean ± standard error of the mean).
HEMI, Cerebral hemispheres; CBLM, cerebellum; BG, basal ganglia; BS, brain stem. *Significantly greater per-
centage recovery than control group, unpaired t test P < .02. †Not significantly different from pre-DHCA value
within group, paired t test P > .19.
Fig 2. Global and regional CMRO2 at 1 hour of reperfusion after 60 minutes of DHCA at 18˚C in control and
PBN groups. Data are expressed as percentage of baseline CBF before DHCA (mean ± standard error of the
mean). HEMI, Cerebral hemispheres; CBLM, cerebellum; BG, basal ganglia; BS, brain stem. *Significantly
greater percentage recovery than control group, unpaired t test P < .04. †Not significantly different from pre-
DHCA value within group, paired t test P > .1.
Finally, in the control group the renal blood flow fell
significantly after DHCA to 80.1% ± 6.2% of the flow
before DHCA (Fig 3).
Effects of PBN. In the PBN group the systemic vas-
cular resistance was higher after DHCA than before
DHCA (0.56 ± 0.04 mm Hg · 100 g · min · mL–1 com-
pared with 0.37 ± 0.02 mm Hg · 100 g · min · mL–1, P =
.0005 before DHCA) and the mean pump flow was
lower (107 ± 7 mL · kg–1 · min–1 compared with 157 ± 8
mL · kg–1 · min–1 before DHCA, P = .001). The change
in pump flow reflects maintenance of the preset level of
CPP at 50 mm Hg despite changes in the systemic vas-
cular resistance. The change in systemic vascular resis-
tance and pump flow in the control and the PBN groups
in opposite directions resulted in a highly significant dif-
ference between the 2 groups after DHCA (P = .0004). 
Recovery of CBF after DHCA in the PBN group was
significantly greater than in the control group globally
and in all brain regions (P < .02) (Fig 1). Recovery of
flow to the cerebellum, brain stem, and basal ganglia
occurred to such an extent that there was no significant
difference between the regional blood flow determined
before and after DHCA in these regions. Global cere-
bral oxygen handling in the PBN group is shown in Fig
4. After DHCA there was no significant change in glob-
al CDO2 (Table II). Regional analysis determined that
only in the cerebral hemispheres, where CDO2 fell
from 5.8 ± 0.3 to 4.1 ± 0.4 mL · 100 g–1 · min–1, was
there a significant difference in CDO2 before and after
DHCA (P = .01). In all regions, the percentage recov-
ery of CDO2 was significantly greater in the PBN group
than in the control group (P < .01). After DHCA in the
PBN group, recovery in CMRO2, both globally and in
all regions, occurred to such an extent that no signifi-
cant difference was detected between the pre-DHCA
and post-DHCA values (P > .1). Regional recovery of
the CMRO2 was significantly higher than in the control
group in all brain regions (P < .04) (Fig 2).
The CVR was higher in the PBN group after DHCA
than before (Table II). When expressed as a percentage
of the baseline CVR before DHCA, however, the
increase was significantly less in the PBN group than in
the control group (133.6% ± 12.3% compared with
190.6% ± 7.1%, P = .002). The rise in CVR in the PBN
group is therefore significantly less than in the control
group. Finally, there was no significant difference
between the mean renal blood flow before and after
DHCA in the PBN group (P = .08) (Fig 3). 
Discussion
The brain is probably the organ most susceptible to
damage by oxygen-derived free radicals. One of the
reasons is that the brain is particularly enriched in
highly peroxidizable fatty acids. In addition, certain
regions of the brain have a higher iron content than
other tissues,15 which is important because the rapid
generation of OH radicals from H2O2 during the
Fenton reaction is dependent on iron (or copper) as a
catalyst. Furthermore, the brain does not contain high
levels of the protective enzymes superoxide dismutase,
catalase, or glutathione peroxidase. Finally, the levels
of ascorbate in the brain are high, which is relevant
because iron can only catalyze the formation of OH
radicals after it has been reduced by ascorbate from
the ferric to ferrous forms. In all, this is a rather bad
combination of factors that leads to promotion of
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Fig 3. Renal blood flow in the control and PBN groups at ini-
tial baseline (Pre-DHCA) and at 1 hour of reperfusion (Post-
DHCA) after 60 minutes of DHCA at 18˚C. Data are
expressed as mean ± standard error of the mean. *Significant
difference from pre-DHCA value within group, paired t test
P = .04. †Significant difference from post-DHCA control
value, unpaired t test P = .03.
Fig 4. Cerebral oxygen handling in the PBN group at initial
baseline (Pre-DHCA) and at 1 hour of reperfusion (Post-
DHCA) after 60 minutes of DHCA at 18˚C. Data are
expressed as mean ± standard error of the mean. *Significant
difference from pre-DHCA value within group, paired t test
P = .05. †Significant difference from post-DHCA control
value, unpaired t test P < .05.
oxidative damage in the brain if disorganization of the
tissue occurs.16
In the current study, after 60 minutes of DHCA at
18˚C and 60 minutes of rewarming in the control
group, the systemic vascular resistance fell and the
pump flow was therefore increased to maintain a con-
stant CPP at the time of CBF measurement. The CVR
rose after DHCA, resulting in a fall in CBF. Production
of free radicals during reperfusion may be responsible
for this reduction in CBF. Damage by oxygen-derived
free radicals during cerebral reperfusion has previous-
ly been shown to be important in the etiology of
reduced CBF (and CMRO2 abnormalities) after
ischemia.17 It is also of interest that the production of
lipid peroxides, which are generated by free radical
damage, after subarachnoid hemorrhage is thought to
be responsible for the subsequent cerebral vasospasm
seen in this condition.18 As the arterial oxygen content
was maintained at a constant level, the reduction in
CBF was primarily responsible for the drop in CDO2
seen in all brain regions after DHCA. Oxygen extrac-
tion was increased and the combination of reduced
CBF and increased CEO2 resulted in a fall in the
CMRO2 in all regions. The finding of impaired CMRO2
is consistent with previous studies of normothermic
global cerebral ischemia-reperfusion injury.17
In the animals that received PBN, the systemic vas-
cular resistance rose significantly after DHCA. The
increase in systemic vascular resistance in the DHCA
group compared with the control group suggests that in
the control group the drop in resistance was due to sys-
temic vasodilatory effects of free radicals. After DHCA
the CBF was significantly greater in the PBN group
than in the control group in all brain regions. This sug-
gests that the reduction of CBF in the control group
was due, at least in part, to an increase in free radical
activity as a result of DHCA. Previous experimental
evidence has shown that PBN results in improvement
in CBF after cerebral ischemia-reperfusion injury.19,20
A study by Inanami and Kuwabara19 showed that PBN
increased CBF in a dose-dependent manner. Further-
more, inhibition of nitric oxide synthase, an enzyme
that produces nitric oxide, resulted in attenuation of the
PBN effect. This suggests that the PBN-induced
increase in CBF is strongly associated with nitric
oxide–related vasodilatation.19 Schulz and associates20
suggested that the vascular endothelium was a primary
target for the damaging action of free radicals. 
Recovery of CDO2 occurred to such an extent both
globally and in all areas of the brain except the cerebral
hemispheres that there was no significant difference
before and after DHCA. This reflects the improvement
in post-DHCA CBF with PBN. After DHCA there was
no significant difference in CMRO2 compared with the
pre-DHCA level. Therefore, when PBN is given before
CPB, a normal cerebral metabolic recovery results after
60 minutes of DHCA. PBN results in a pronounced
recovery of energy state after focal cerebral ischemia,
with both adenosine triphosphate and lactate contents
approaching normal.21 The improvement in metabolic
recovery with PBN is thought to be due to the effect of
the spin trap at the mitochondrial level.22
PBN improves the histologic and neurobehavioral
recovery in both focal and global models of cerebral
ischemia. The size of the infarct is reduced after both
permanent and transient middle cerebral artery occlu-
sion.20,23 In addition, a reduction in cerebral edema,
attenuation of neuronal damage in the CA1 area of the
hippocampus, and improvement in neurologic behavior
test results have been demonstrated with PBN after
cerebral ischemic injury.23-25 In one study a significant
improvement in neurobehavioral score was seen even
when PBN was given 12 hours after the ischemic
episode.23 In combination, these findings demonstrate
that PBN has a strong neuroprotective effect and sup-
port the hypothesis that free radicals play an important
role in brain injury after cerebral ischemia.
In addition to the beneficial effects of PBN that have
been demonstrated in models of cerebral ischemia, its
use has been shown to provide protection for other
organs including the heart,26,27 lungs,28 and kidneys29
in a variety of experimental models. In the current
study, a significant improvement in renal blood flow
was noted in the PBN group after DHCA. This effect
has the potential to reduce renal morbidity after DHCA
and could have important implications in pediatric car-
diac surgical practice. 
Free radicals are known to contribute to tissue injury
in a wide variety of pathologic conditions including
trauma, Parkinson disease, arthritis, carcinogenesis,
ionizing radiation, ozone damage, and aging. In addi-
tion, there is now considerable evidence that oxygen-
derived free radicals are responsible for cell damage in
the course of cerebral ischemia. This study suggests
that free radicals are involved in the impairment in
cerebral recovery that follows a period of DHCA, and
the null hypothesis stated previously can be rejected.
The most likely mechanism of improved outcome after
treatment with PBN in the current study is attenuation
of free radical injury; however, other unknown effects
of the drug cannot be completely excluded. This is the
first study in the context of CPB to implicate free radi-
cals in cerebral damage. A remarkable improvement in
CBF and CMRO2 after DHCA was demonstrated with
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the use of PBN in the neonatal piglet. This suggests that
free radical scavengers could have enormous potential
as cerebral neuroprotectants in patients undergoing
surgery with the use of DHCA.
We thank Ronnie Johnson for his technical help during
these experiments.
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Discussion
Dr F. Mark Lupinetti (Seattle, Wash). Is it possible that
conventional treatment fortuitously achieves the same bene-
fits that PBN does? Your model does not include agents such
as steroids, barbiturates, or mannitol, which are commonly
used in clinical practice. Would the inclusion of these agents
overcome the benefits of PBN?
Dr Langley. The main reason for not using other poten-
tially neuroprotective strategies was that we wanted to maxi-
mize the injury caused by DHCA in the control group. You
mentioned barbiturates, mannitol, and steroids, but there are
a number of other mechanisms that we could also have eval-
312 Langley et al The Journal of Thoracic and
Cardiovascular Surgery
February 2000
uated. Dr Jonas’ group in Boston has looked at aprotinin and
N-methyl-D-aspartate antagonists, monoclonal antibodies to
CD18, and our own group has investigated the beneficial
effects with thromboxane A2 antagonists and platelet activat-
ing factor antagonists. One of the problems of using a com-
bination of strategies was determining which of the chemicals
or compounds is producing the effect. We wanted to create a
study that was very clear-cut, without any potentially con-
founding variables.
Dr Lupinetti. My second question is a little more philo-
sophical. As we focus more carefully on brain protection, how
can we avoid the unfortunate situation that currently exists in
the field of myocardial protection? As you know, more than
1000 agents have been tested as possibly benefiting the
ischemic heart and, remarkably enough, all of them work.
This has generated numerous publications but relatively little
patient benefit. I would appreciate your thoughts regarding
how we might better compare competing strategies of cerebral
protection and ultimately improve our clinical outcomes.
Dr Langley. That is a very interesting question and one
that is difficult to answer. I am not entirely sure at the pre-
sent time, however, whether an analogy between myocardial
protection and cerebral protection is quite fair. Cerebral neu-
roprotection during cardiac surgery is fairly poorly under-
stood. It is extremely complicated, and our comprehension
of the mechanisms involved is still in its infancy. With
respect to the research in the field of myocardial protection,
I do not think we are talking here about adding a bit of mag-
nesium or adding a bit of calcium to a cardioplegic solution.
The current study demonstrates interruption of what is pos-
sibly the most important pathway leading to cerebral injury
after ischemia. This study has demonstrated that free radi-
cals are involved in the impairment of cerebral recovery and
that a free radical scavenger, in this instance PBN, can pro-
tect the brain from free radical–mediated damage. I do not
think it is necessary to investigate a whole battery of differ-
ent free radical scavengers. The mechanism has been fairly
convincingly demonstrated. We are eager to undertake one
further animal experiment, a survival model in which we
could evaluate neurobehavioral outcomes. After this, we are
eager to move fairly rapidly into clinical applications of our
findings.
Dr Vaughn Starnes (Los Angeles, Calif). I have two com-
ments about how you did the study. 
Do you know whether PBN has any vasodilatory effect
itself? You controlled perfusion on the basis of pressure and
not flow. Were the flow characteristics in the 2 groups dif-
ferent? In other words, did the PBN-treated group get 30%
more blood flow because you were controlling pressure, not
flow?
Dr Langley. We deliberately controlled CPP because it has
previously been clearly demonstrated that cerebral perfusion
is determined by perfusion pressure rather than by flow rate.
The pump flow rate was actually significantly lower in the
PBN group than in the control group.
Dr Starnes. Was there a flow difference in the 2 groups?
Dr Langley. Yes, there was. In the control group the sys-
temic vascular resistance fell after DHCA. This fall necessi-
tated a rise in pump flow rate to maintain the preset CPP of
50 mm Hg. In the PBN group the systemic vascular resis-
tance was higher after DHCA and the pump flow rate was
therefore reduced. The improved CBF in the PBN group can
therefore not be attributed to an increase in pump flow rate.
Dr W. R. Eric Jamieson (Vancouver, British Columbia,
Canada). Would you give some consideration to evaluating
the two current clinical techniques—retrograde cerebral per-
fusion under profound hypothermia and direct arterial reper-
fusion under moderate hypothermia—and use the same
model to assess these two current clinical parameters of
management? 
Dr Langley. Yes, we would. I think it would be very inter-
esting to do that. 
Dr Frank Pigula (Pittsburgh, Pa). Did you evaluate the
metabolic state of the brain in any other way in terms of glu-
cose metabolism or lactate production? Did you evaluate the
potential for edema in the brain after DHCA?
Dr Langley. We did not evaluate lactate levels in this study.
In the study that we presented to the Southern Thoracic
Surgical Association in November 1998, which will be pub-
lished in the Annals of Thoracic Surgery, we demonstrated a
correlation between cerebral ultrastructure in the brain and
CMRO2. We found that an abnormal CMRO2 was associated
with perivascular and intracellular organelle edema and that
when the CMRO2 recovered to a normal level there was a
remarkable recovery in the ultrastructural findings in the
brain. We believe that the normal recovery of CMRO2 in this
study would be associated with a normal cerebral perivascu-
lar ultrastructural recovery.
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